PROT Proteonomix, Inc.

[luckyhousewife]

PROT NEWS:Proteonomix, Inc. (PROT) to Move Forward With Offshore Stem Cell Testing

MOUNTAINSIDE, NJ, Oct 19, 2011 (MARKETWIRE via COMTEX) -- PROTEONOMIX, INC. /quotes/zigman/522094 PROT +10.77% , a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD"), in the United States.
Michael Cohen, President of the Company, stated: "Since we progress toward the commencement of our trial of UMK-121 in the United States, we have decided to explore the possible testing of our cardiac treatment offshore in order to reduce the cost of bringing the cardiac treatment to market. This strategic decision is being made in recognition of the increasing costs associated with bringing a new drug to market in the United States through the NDA (New Drug Application) process and the availability of expert medical testing capabilities offshore at a fraction of the cost."
Mr. Cohen continued: "Once we have established the efficacy of our cardiac stem cell treatment offshore and have commenced foreign sales, then we will be in a better financial position to pursue the NDA in the United States." We have been approached by one group that has expressed interest in exploring such a possibility and we will follow through with this in the coming weeks. Meanwhile, we will seek out others interested in a similar transaction keeping in mind at all times that any such deal would have to provide immediate benefit to our shareholders."
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/ , http://www.proteoderm.com/ , http://www.otcqb.com/ and http://www.sec.gov/ .
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.



Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact





SOURCE: Proteonomix

[luckyhousewife]

PROT's Top Highlights

(1) PROT reported that it has developed a catalog of intellectual properties and patent applications

(2) PROT’s StromCel(T) cellular materials has given some indications as a general anti-inflammatory

(3) PROT stated that it is forming an international network of Stem Cell Laboratories

(4) PROT reported that it is examining the licensing of Diabetes Stem Cell Technology

(5) PROT’s wholly-owned subsidiary has opened its retail website and has started accepting orders for its anti-aging line of skin care products

(6) PROT has reported that it has formed a new subsidiary to enter the Pharmaceutical Market



Licensing of Diabetes Stem Cell Technology

PROThas recently announced that it is looking at the possibility of licensing its stem cell diabetes related technology to another company. The plans to license the technology come as the company continues progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (ESLD).

Michael Cohen, President of PROT, recently said that "since the company continues its rapid progress toward the start of its trial of UMK-121, it has decided to explore the possible licensing of its diabetes related applications of its stem cell technology to another company."

Cohen said that "the strategic decision is being made in recognition of the increasing breadth of the company’s technology and the requirement for further capital and management resources to effectively deal with the massive ramifications of the diabetes applications of the stem cell technology company has developed."

[Jav992]

[luckyhousewife]

PROT AH NEWS:
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
print
Proteonomix (OTCBB:PROT)
Intraday Stock Chart
Today : Friday 11 November 2011

PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Cosmetic Ingredients Review Board ("CIR") has approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States.

Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."

Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.

Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."

Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.


Contact:



Proteonomix, Inc

[luckyhousewife]

PROT: 8-k on friday's news!!:http://ih.advfn.com/p.php?pid=nmona&...luckyhousewife

Posts: 478
Joined: Mon Mar 01, 2010 9:47 am
Private messageE-mail luckyhousewife

[chuck44l]

MOUNTAINSIDE, NJ--(Marketwire -11/21/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has entered into an agreement with the University of Miami ("The University") to conduct a Clinical Study entitled "UMK 121 in Patients with Liver Disease."

Under the agreement The Company and The University have agreed to conduct a clinical study entitled "UMK 121 in Patients with Liver Disease." The University will pay expenses associated with the clinical study and The Company shall contribute $105,000 to assist with the clinical study.

Michael Cohen, President of the Company, stated: "We would like to thank the University for their generous assistance and agreement to conduct a clinical trial of UMK-121. The Company has previously described, the terms of the agreement to license, develop and the patent application of the UMK 121 technology. The Company will work together with the University and the principal investigators to initiate the clinical study."

Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is advancing toward its first clinical trial in ESLD ('End Stage Liver Disease') patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months The Company is working diligently to advance this product line into a clinical trial."

About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

About the University of Miami:
A private research university with more than 15,000 students from around the world, the University of Miami is a vibrant and diverse academic community focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. Led by President Donna E. Shalala, the University is comprised of 12 schools and colleges serving undergraduate and graduate students in more than 180 majors and programs. In 2011, U.S.News & World Report ranked UM No. 38 in its "Best Colleges" listings, and it continued to be ranked as the top school in Florida; it also cited several of its programs in "America's Best Graduate Schools." In the past 10 years, UM has moved up 29 spots in the "Best Colleges" rankings. Established in 1925 during the region's famous real estate boom, UM is a major research university engaged in nearly $339 million in research and sponsored program expenditures a year. While the majority of this work is housed at the Miller School of Medicine, investigators conduct dozens of studies in other areas. For more information please visit www.miami.edu

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact:

Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact

[chuck44l]

22-Nov-2011

Other Events



Item 8.01 - Other Events
Proteonomix, Inc. (the "Company") issued a press release, dated November 21, 2011, entitled- "Proteonomix, Inc. (PROT) Announces Material Agreement with the University of Miami to Conduct a Clinical Study of UMK 121 in Patients with End Stage Liver Disease" The press release is in its entirety below:

Proteonomix, Inc. (PROT) Announces Material Agreement with the University of Miami to Conduct a Clinical Study of UMK 121 in Patients with End Stage Liver Disease

MOUNTAINSIDE, NJ, November 21, 2011 -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has entered into an agreement with the University of Miami ("The University") to conduct a Clinical Study entitled "UMK 121 in Patients with Liver Disease."

Under the agreement The Company and The University have agreed to conduct a clinical study entitled "UMK 121 in Patients with Liver Disease." The University will pay expenses associated with the clinical study and The Company shall contribute $105,000 to assist with the clinical study.

Michael Cohen, President of the Company, stated: "We would like to thank the University for their generous assistance and agreement to conduct a clinical trial of UMK-121." The Company has previously described, the terms of the agreement to license, develop and the patent application of the UMK 121 technology. The Company will work together with the University and the principal investigators to initiate the clinical study."

Mr. Cohen continued, "Our UMK-121 pharmaceutical therapy is advancing toward its first clinical trial in ESLD ("End Stage Liver Disease") patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months The Company is working diligently to advance this product line into a clinical trial".

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, National Stem Cell, PRTMI and THOR Biopharma. Proteoderm, Inc. is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel, Inc. develops therapeutic modalities for the treatment of Cardiovascular Disease (CVD). National Stem Cell, Inc. is Proteonomix's operating subsidiary. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

About the University of Miami:

A private research university with more than 15,000 students from around the world, the University of Miami is a vibrant and diverse academic community focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. Led by President Donna E. Shalala, the University is comprised of 12 schools and colleges serving undergraduate and graduate students in more than 180 majors and programs. In 2011, U.S.News & World Report ranked UM No. 38 in its "Best Colleges" listings, and it continued to be ranked as the top school in Florida; it also cited several of its programs in "America's Best Graduate Schools." In the past 10 years, UM has moved up 29 spots in the "Best Colleges" rankings. Established in 1925 during the region's famous real estate boom, UM is a major research university engaged in nearly $339 million in research and sponsored program expenditures a year. While the majority of this work is housed at the Miller School of Medicine, investigators conduct dozens of studies in other areas. For more information please visit www.miami.edu

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

[chuck44l]

View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010
Total Revenue 7 4 8 14
Cost of Revenue 31 4 3 14

Gross Profit (24) 0 5 1

Operating Expenses
Research Development - - - -
Selling General and Administrative 260 159 191 914
Non Recurring - - - -
Others 95 95 94 234

Total Operating Expenses - - - -


Operating Income or Loss (379) (255) (280) (1,147)

Income from Continuing Operations
Total Other Income/Expenses Net - - - -
Earnings Before Interest And Taxes (400) (274) (299) (1,147)
Interest Expense - - - -
Income Before Tax (400) (274) (299) (1,147)
Income Tax Expense - - 0 -
Minority Interest - - - -

Net Income From Continuing Ops (400) (274) (300) (1,147)

Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -


Net Income (400) (274) (300) (1,147)
Preferred Stock And Other Adjustments - - - -

Net Income Applicable To Common Shares (400) (274) (300) (1,147)


Currency in USD.

[chuck44l]

MOUNTAINSIDE, NJ--(Marketwire -12/07/11)- Proteonomix, Inc. (OTC.BB: PROT.OB - News) sends letter to its shareholders.

Dear Shareholders:

This has been a momentous year for your Company. During the past several years we have asserted that our business lines would move forward in both the cosmetic area via our Proteoderm subsidiary and in the biopharmaceutical lines, most recently our UMK-121 technology.

Earlier this month the Company announced that it had entered into an agreement with a leading University ("The University") to conduct a Clinical Study entitled "UMK-121 in Patients with Liver Disease." Under the agreement The Company and The University agreed to conduct a clinical study entitled UMK-121 in Patients with Liver Disease. The University will pay expenses associated with this clinical study and the Company shall contribute $105,000 to assist with the clinical study. The University was most generous in assuming the vast majority of the costs associated with the clinical study. The Company believes that the University's action demonstrates that the University has a high degree of confidence in the potential of UMK-121.

The Company has previously described the terms of the agreement to license and develop and the patent application of the UMK 121 technology. This first clinical trial will be in ESLD ("End Stage Liver Disease") patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months. In addition to ESLD we also believe that UMK-121 may have applications to the amelioration of disease processes in other organs, such as the kidneys and the heart. Further clinical studies will be required before moving UMK-121 to commercialization.

Yet another major achievement was made by the Company in early November when the Cosmetic Ingredients Review Board ("CIR") approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States. The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA.

Proteoderm, Inc. has already developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in Cosmeceutical products.

Our plan to market the Proteoderm products centers on partnering with other cosmetic manufacturers. This partnering process has already been greatly enhanced by the issuance of the INCI name. Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.

The Company also engaged the services of Gilford Securities Inc. in July to act as the Company's investment banking adviser for the purposes of assisting and advising the Company on enhancing shareholder value.

In summary, we have started to deliver on the promise of our technologies and expect that in the near future we will have confirmation via the human clinical study of the safety and perhaps even the efficacy of our UMK-121. We also anticipate making substantial progress in moving our Proteoderm NC-138 into commercial use during 2012.

On behalf of the Board of Directors Of Proteonomix, Inc.

/s/ Michael Cohen

Michael Cohen
Chairman, Board of Directors

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact:

Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email: Email Contact

[chuck44l]

9-Dec-2011

Other Events



Item 8.01 - Other Events
Proteonomix, Inc. (the "Company") issued a press release, dated December 7, 2011, entitled- "Proteonomix, Inc. (PROT) Letter to Shareholders." The press release is in its entirety below:


Proteonomix, Inc. (PROT) Letter to Shareholders
MOUNTAINSIDE, NJ--(Dec 7, 2011) - Proteonomix, Inc. (OTCBB: PROT) sends letter to its shareholders.

Dear Shareholders:

This has been a momentous year for your Company. During the past several years we have asserted that our business lines would move forward in both the cosmetic area via our Proteoderm subsidiary and in the biopharmaceutical lines, most recently our UMK-121 technology.

Earlier this month the Company announced that it had entered into an agreement with a leading University ("The University") to conduct a Clinical Study entitled "UMK-121 in Patients with Liver Disease." Under the agreement The Company and The University agreed to conduct a clinical study entitled UMK-121 in Patients with Liver Disease. The University will pay expenses associated with this clinical study and the Company shall contribute $105,000 to assist with the clinical study. The University was most generous in assuming the vast majority of the costs associated with the clinical study. The Company believes that the University's action demonstrates that the University has a high degree of confidence in the potential of UMK-121.

The Company has previously described the terms of the agreement to license and develop and the patent application of the UMK 121 technology. This first clinical trial will be in ESLD ("End Stage Liver Disease") patients. The Company hopes to provide information about the clinical study in the upcoming weeks and months. In addition to ESLD we also believe that UMK-121 may have applications to the amelioration of disease processes in other organs, such as the kidneys and the heart. Further clinical studies will be required before moving UMK-121 to commercialization.

Yet another major achievement was made by the Company in early November when the Cosmetic Ingredients Review Board ("CIR") approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States. The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA.

Proteoderm, Inc. has already developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in Cosmeceutical products.

Our plan to market the Proteoderm products centers on partnering with other cosmetic manufacturers. This partnering process has already been greatly enhanced by the issuance of the INCI name. Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.

The Company also engaged the services of Gilford Securities Inc. in July to act as the Company's investment banking adviser for the purposes of assisting and advising the Company on enhancing shareholder value.

In summary, we have started to deliver on the promise of our technologies and expect that in the near future we will have confirmation via the human clinical study of the safety and perhaps even the efficacy of our UMK-121. We also anticipate making substantial progress in moving our Proteoderm NC-138 into commercial use during 2012.

On behalf of the Board of Directors Of Proteonomix, Inc.

/s/ Michael Cohen

Michael Cohen
Chairman, Board of Directors

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.